Trials / Unknown
UnknownNCT03684772
Topical Ionic Contra-Viral Therapy in Actinic Keratosis
A Phase 2, Randomized, Double Blind, Vehicle Controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics and Safety of Topical Ionic Contra-Viral Therapy (ICVT) Comprised of Digoxin and Furosemide in Actinic Keratosis
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Maruho Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
To explore the pharmacodynamics and evaluate safety, tolerability and clinical efficacy of ICVT comprised of digoxin and furosemide (dual agent), digoxin (single agent), furosemide (single agent) in patients with AK.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICVT Topical Gel | Digoxin and Furosemide (0.125%) |
| DRUG | Furosemide Topical Gel | Furosemide (0.125%) |
| DRUG | Digoxin Topical Gel | Digoxin (0.125%) |
| DRUG | Vehicle Topical Gel | Vehicle Gel |
Timeline
- Start date
- 2018-10-22
- Primary completion
- 2019-09-01
- Completion
- 2019-09-01
- First posted
- 2018-09-26
- Last updated
- 2019-05-01
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03684772. Inclusion in this directory is not an endorsement.